Europe Molecular Diagnostics Market by Products (Reagents, Instruments, and Others), Test Locations (Self-test, Point of Care, and Central Laboratories), Technology (Isothermal Nucleic Acid Amplification Technology, PCR, Multiplex PCR, In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, Transcription-mediated Amplification, and Sequencing), Applications (Microbiology, Cardiovascular Disease, Pharmacogenomics, Infectious Diseases, Neurological Disease, and Others), and Geography (the UK, Germany, Italy, France, the Netherlands, and Rest of Europe) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031
Europe Molecular Diagnostics Market Outlook 2031:
The Europe molecular diagnostics market size was valued at USD 2.91 Billion in 2022 and is projected to reach USD 6.32 Billion by 2031, expanding at a CAGR of 9% during the forecast period 2023 - 2031. The growth of the market is attributed to the increasing prevalence of diabetes, chronic diseases, cardiovascular, and other uncommunicable diseases.
Molecular diagnostics refers to the techniques in which biological markers are analyzed and applied for diagnostic and treatment purposes of infectious diseases as well as chronic illness. Scientific testing by applying molecular biology helps to diagnose & monitor disorders, mitigate risk, identify patients-based treatments along with agricultural biosecurity to monitor crop disease and take corrective measures.
As per the Health Protection Report 2019, more than 447,694 new sexually transmitted infection (STI) diagnoses were reported in England. Out of these, Chlamydia cases constituted nearly 218,095, which was around 49% of all new STI diagnoses, gonorrhea cases were 56,259 representing around 13%, first episode genital warts were 57,318 cases representing around 13%, and genital herpes were 33,867 around 8%.
The COVID-19 outbreak, as an infectious disease, which was started in Wuhan (China) in December 2019 has become global pandemic in matter of few weeks. The COVID-19 pandemic had a positive impact on the molecular diagnostics market due to the usage of molecular diagnostic techniques for novel corona virus testing. The number of tests and sales of reagents got affected due to the lockdowns caused by the pandemic globally.
However, surge in demand for diagnostic kits for COVID-19 testing across the globe due to strict regulations such as mandatory use of testing for travelers using commercial flights present a key aspect for the market development.
Regulatory authorities have formulated policies to speed up approval of diagnostic products in both developing and developed countries. Several competitors in the healthcare industry have invested a massive funding to develop rapid tests for the virus as it becomes a need of the hour, which is expected to lower the negative impact of the pandemic on their operational capabilities and sustain their revenues.
Molecular Diagnostics Market Trends, Drivers, Restraints, and Opportunities
- Increasing infectious diseases and chronic illness such as cancer in developed and developing regions is anticipated to upsurge the market growth.
- Rising demand for molecular diagnostics to diagnose various cancer and genetic diseases is projected to propel the market growth in the coming years.
- Technological advancement and new products development by key market players to enhance the diagnostic methods and procedures are major factors for accelerating the market growth.
- Expensive diagnosis instruments and high maintenance cost involved in molecular diagnostics that can only be afforded by large hospitals and laboratories, which adversely impact the market. This is expected to hinder the market expansion.
- Lack of skilled workers and delaying in molecular diagnosis tests approvals from regulatory bodies in some developed countries are the main challenges hampering the market growth.
- Demand for companion diagnostics is growing as these devices assist the healthcare providers to make informed decisions for patient-based treatment using appropriate therapy. This is projected to boost the market.
Scope of Molecular Diagnostics Market Report
The report on the Europe molecular diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Europe Molecular Diagnostics Market -Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Products (Reagents, Instruments, and Others), Test Locations (Self-test, Point of Care, and Central Laboratories), Technology (Isothermal Nucleic Acid Amplification Technology, PCR, Multiplex PCR, In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, Transcription-mediated Amplification, and Sequencing), Applications (Microbiology, Cardiovascular Disease, Pharmacogenomics, Infectious Diseases, Neurological Disease, and Others) |
Geographical Scope |
The UK, Germany, Italy, France, the Netherlands, and Rest of Europe |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Dako, Bayer AG; Abbott Laboratories; Alere, Inc.; Hologic, Inc. (Gen probe); Danaher Corporation; Sysmex Corp.; Becton, Dickinson and Co.; Novartis AG; Johnson and Johnson; Qiagen N.V.; Cephid; Roche Diagnostics; and bioMérieux SA |
Molecular Diagnostics Market Segment Insights
Reagents segment is projected to expand substantially
On the basis of products, the market is segmented into instrument, reagents, and others. The reagents segment is projected to expand substantially in the market in the coming years owing to technological advancement in the diagnostic process to examine multiple diseases.
The commonly used reagents include salts, formamide, SDS, dextran, and sulphate or heparin, to perform in-situ hybridization assays. Thus, the increasing demand for usage of techniques comprising fluorescence in situ hybridization present another key factor boosting the growth of the reagents segment.
Central Laboratories segment is anticipated to propel the market growth
Based on test Locations, the Europe molecular diagnostic market is segmented into self-test, point of care, and central laboratories. The central laboratories segment is anticipated to propel the market growth during the forecast period owing to the increasing number of trained professionals, higher patient footfall, and advanced facilities of laboratory.
Moreover, the expansion of multiple clinical laboratory assays and easy availability of the advanced assays to perform molecular diagnosis of various illnesses are expected to boost the segment growth in the coming years.
On the other hand, the point of care segment is expected to upsurge at a considerable CAGR during the forecast period. Factors such as increasing demand for quick diagnosis, as well as the availability of newly developed PoC technology to monitor treatment reactions in patients having cardiac problem, are some key factors for driving segment growth.
PCR segment is anticipated to register a substantial growth rate
In terms of technology, the market is categorized as isothermal nucleic acid amplification technology, PCR, multiplex PCR, in situ hybridization, chips & microarrays, mass spectrometry, transcription-mediated amplification, and sequencing.
The PCR segment is anticipated to register a substantial growth rate during the forecast period owing to rising adoption of the test for detecting infectious diseases especially the COVID virus. Moreover, wide application of the technology in molecular diagnostics research and study present another key factor boosting the segment growth.
Infectious disease segment is expected to register a large market share
Based on applications, the Europe molecular diagnostics market is segregated as microbiology, cardiovascular disease, pharmacogenomics, infectious diseases, neurological disease, and others. The infectious disease segment is expected to register a large market share during the forecast period due to the rising cases of infectious disease including HIV and other flu or viral diseases.
Moreover, the improvement in diagnostics test for the detection of infectious disease is anticipated to boost the segment growth. Meanwhile, the cardiovascular disease segment is projected to hold a major share of the market in the coming years due to increasing prevalence of cardiac arrest and heart-related diseases especially in the developed countries. Increasing demand for early and efficient diagnosis for detection of heart disease is further projected to escalate the segment expansion.
Germany is projected to dominate the market
In terms of regions, the Europe molecular diagnostics market is classified as the UK, Germany, Italy, France, the Netherlands, and Rest of Europe. Germany is projected to dominate the market, expanding at a rapid pace during the forecast period owing to rise in adoption of technological advancements in diagnostic kits and extensive research studies in the field of molecular diagnostics.
The UK, being the second major country generating high market revenue, is expected to register a substantial growth rate in the market during the forecast period. The presence of well-developed healthcare infrastructure, increasing disposable income, and the rising awareness regarding the benefits for the early diagnosis of diseases including cancer and HIV especially in the UK and Germany are the key factors contributing towards the growth of the overall regional market.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Molecular Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Molecular Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Molecular Diagnostics Market - Supply Chain
4.5. Global Molecular Diagnostics Market Forecast
4.5.1. Molecular Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Molecular Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Molecular Diagnostics Market Absolute $ Opportunity
5. Global Molecular Diagnostics Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Molecular Diagnostics Market Size and Volume Forecast by Applications
5.3.1. Microbiology
5.3.2. Cardiovascular Disease
5.3.3. Pharmacogenomics
5.3.4. Infectious Diseases
5.3.5. Neurological Disease
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Molecular Diagnostics Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Molecular Diagnostics Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Molecular Diagnostics Demand Share Forecast, 2019-2026
7. North America Molecular Diagnostics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Molecular Diagnostics Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Molecular Diagnostics Market Size and Volume Forecast by Applications
7.4.1. Microbiology
7.4.2. Cardiovascular Disease
7.4.3. Pharmacogenomics
7.4.4. Infectious Diseases
7.4.5. Neurological Disease
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Molecular Diagnostics Demand Share Forecast, 2019-2026
8. Latin America Molecular Diagnostics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Molecular Diagnostics Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Molecular Diagnostics Market Size and Volume Forecast by Applications
8.4.1. Microbiology
8.4.2. Cardiovascular Disease
8.4.3. Pharmacogenomics
8.4.4. Infectious Diseases
8.4.5. Neurological Disease
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Molecular Diagnostics Demand Share Forecast, 2019-2026
9. Europe Molecular Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Molecular Diagnostics Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Molecular Diagnostics Market Size and Volume Forecast by Applications
9.4.1. Microbiology
9.4.2. Cardiovascular Disease
9.4.3. Pharmacogenomics
9.4.4. Infectious Diseases
9.4.5. Neurological Disease
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Molecular Diagnostics Demand Share Forecast, 2019-2026
10. Asia Pacific Molecular Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Molecular Diagnostics Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Molecular Diagnostics Market Size and Volume Forecast by Applications
10.4.1. Microbiology
10.4.2. Cardiovascular Disease
10.4.3. Pharmacogenomics
10.4.4. Infectious Diseases
10.4.5. Neurological Disease
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Molecular Diagnostics Demand Share Forecast, 2019-2026
11. Middle East & Africa Molecular Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Molecular Diagnostics Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Molecular Diagnostics Market Size and Volume Forecast by Applications
11.4.1. Microbiology
11.4.2. Cardiovascular Disease
11.4.3. Pharmacogenomics
11.4.4. Infectious Diseases
11.4.5. Neurological Disease
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Molecular Diagnostics Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Molecular Diagnostics Market: Market Share Analysis
12.2. Molecular Diagnostics Distributors and Customers
12.3. Molecular Diagnostics Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Bio-Rad Laboratories, Inc.
12.4.2. Siemens Healthcare GmbH
12.4.3. Dako, Bayer AG
12.4.4. Abbott Laboratories
12.4.5. Alere, Inc.
12.4.6. Hologic, Inc. (Gen probe)
12.4.7. Danaher Corporation